VIDEO: Suprachoroidal delivery ‘brings gene therapy into the office setting’ for wet AMD
In a video interview, Nancy M. Holekamp, MD, director of retina services at Pepose Vision Institute in St. Louis, talked about suprachoroidal delivery of Regenxbio’s gene therapy RGX-314 for neovascular age-related macular degeneration.
The results presented at the ASRS annual meeting revealed that the treatment could get enough viral particles into the suprachoroidal space, which would “infect enough cells to create the biofactory that then produces something similar to ranibizumab,” Holekamp told Healio.
“We all know that the suprachoroidal injector is elegant, but it’s not like an anti-VEGF injection — it does require some training, it does require some skill [and] it will take a little more time,” Holekamp said. “But it still brings gene therapy into the office setting, which is an extremely exciting prospect for treating wet AMD patients in this fashion.”
Collapse
Barakat, M. Suprachoroidal delivery of RGX-314 for neovascular AMD: Initial results from the phase II AAVIATE study. Presented at: American Society of Retina Specialists meeting; Oct. 8-12, 2021; San Antonio.
Read more about